177Lu PSMA vs Cabazitaxel for mCRPC: ... - Fight Prostate Ca...

Fight Prostate Cancer

3,020 members1,471 posts

177Lu PSMA vs Cabazitaxel for mCRPC: real-world data

Maxone73 profile image
0 Replies

In a nutshell....

If you can get both, get both (median OS = 29.6 months)

If you have to choose, choose 177Lu-PSMA (median OS 16.5 vs 14.7 months for cabazitaxel alone)

I am not sure it's a meaningful impact, I would try to get both, but I must find if they can give an indication about the sequeence.

More details here: prostatewarriors.com/2025/0...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Phase 3 ended: ECLIPSE trial of 177Lu-PSMA-I&T

A phase 3 clinical trial called ECLIPSE has shown that 177Lu-PSMA-I&T significantly extends the...
Maxone73 profile image

Apalutamide as first-line treatment, real-world data

Because sometimes it's nice to know the actual outcomes in day to day clinical practice. A...
Maxone73 profile image

Phase 1 ACCEL trial recruiting: AC-225-PSMA-62 for OLIGOMETASTATIC HSPC and mCRPC

I am not oligometastatic, dammit! But this could really be something worth trying! It is, at least...
Maxone73 profile image

ASCO Gu 2025: real world data confirms that undetectable PSA nadir is a strong predictor of outcomes

Real world seems to confirm clinical trial data in this case! A real-world study from the IRONMAN...
Maxone73 profile image

Revisiting the ORIOLE trial--SBRT vs Observation--Key Take Home points for the Oligometastatic PCa patient

Hello FPC members, After exchanging messages with another member, I wanted to review again the...
NPfisherman profile image